Crown Laboratories, Inc., a privately held player in the skincare industry, agreed on Monday to acquire Revance Therapeutics, Inc. RVNC.

护肤行业的私营企业皇冠实验室（CrownLaboratories，Inc.）周一同意收购Revance Therapeutics，Inc.RVNC。

Under the terms of the agreement, Crown will commence a tender offer to acquire all outstanding shares of Revance’s common stock for $6.66 per share in cash, representing a total enterprise value of $924 million.

根据协议条款，皇冠将开始要约收购Revance普通股的所有流通股，每股现金6.66美元，企业总价值9.24亿美元。

The purchase price represents a premium of 89% over Revance’s closing market price on Aug. 9, 2024, and a 111% premium to Revance’s 60-day volume-weighted average price.

购买价格比Revance 8月的收盘价高出89%。2024年，比Revance的60天成交量加权平均价格溢价111%。

Also Read: Botox And Similar Injections Have Associated Risks: Consumer Group Pushes for Stronger Warnings.

另请阅读：肉毒杆菌毒素和类似的注射都有相关的风险：消费者团体要求发出更强烈的警告。

Revance Therapeutics’ lead product, Daxxify (daxibotulinumtoxinA-Ianm) injection, is indicated to treat frown lines. It competes with AbbVie Inc’s ABBV Botox.

Revance Therapeutics的主要产品Daxxify（daxibotulinumtoxinA Ianm）注射液用于治疗皱纹。它与AbbVie公司的ABBV肉毒杆菌毒素竞争。

The FDA approved Revance’s Daxxify in September 2022.

FDA于2022年9月批准了Revance的Daxxify。

Revance’s Daxxify is known for its longer-lasting effects, lasting approximately six months, almost double the duration of Botox.

Revance的Daxxify以其持久的效果而闻名，持续约六个月，几乎是肉毒杆菌毒素持续时间的两倍。

In the second quarter of 2024, Daxxify generated sales of $28.69 million, up from $22.63 million a year ago. Daxxify aesthetic units sold increased 65% year-over-year and 15% sequentially; over 3,700 ordering accounts were reached.

2024年第二季度，Daxxify的销售额为2869万美元，高于一年前的2263万美元。Daxxify美学单元销售额同比增长65%，依次增长15%；达到3700多个订购账户。

Jeff Bedard, founder and Chief Executive Officer of Crown, praised Revance for its “impressive track record in developing innovative aesthetics offerings that will complement Crown’s innovative line of skincare products.”

Crown创始人兼首席执行官杰夫·贝达德（Jeff Bedard）称赞Revance“在开发创新美学产品方面取得了令人印象深刻的业绩，这将补充Crown的创新护肤产品系列。”

The transaction is expected to close by year-end. Following the merger, Revance will be wholly owned by Crown, and its stock will no longer be publicly traded on Nasdaq.

该交易有望在年底前完成。合并后，Revance将由Crown全资拥有，其股票将不再在纳斯达克公开交易。

Price Action: RVNC stock is up 86.3% at $6.57 at last check Monday.

价格走势：在周一的最后一次检查中，RVNC股价上涨86.3%，至6.57美元。

Read Next:

阅读下一页：

Delay Hits Humacyte’s Bioengineered Human Tissue Implant For Vascular Trauma Injuries, FDA Extends Time To Review.

美国食品和药物管理局（FDA）延长了审查时间，Humacyte的生物工程人体组织植入物因血管创伤而延迟。

Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Benzinga API为您带来的市场新闻和数据©2024 Benzinga.com。Benzinga不提供投资建议。保留所有权利。